Teva Pharmaceuticals has announced new real-world data evaluating treatment continuity, Health Care Resource Utilisation (HCRU) and clinical outcomes among adults with schizophrenia and Bipolar I Disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and health care costs compared with other treatment options. The new findings were presented at Psych Congress, held from September 15 to 19, 2026, in New Orleans, LA.

Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer, Teva Pharmaceuticals, said, “We cannot accept psychiatric emergencies and hospitalisations as an inevitable part of living with schizophrenia and Bipolar I Disorder. These findings show that when we provide a treatment option like UZEDY that helps patients stay on track, we can meaningfully cut emergency room visits and help people maintain stability in their everyday lives. Delivering measurable impact for patients and healthcare systems is what drives everything we do at Teva.”

The two schizophrenia abstracts featured at Psych Congress highlight significant clinical and economic advantages in real-world settings.

In a matched cohort of 1,166 patients (583 per group), fewer patients receiving once-monthly UZEDY had an Emergency Department (ED) visit compared to PP1m (22 percent vs. 27.8 percent). Overall, UZEDY patients had a 40 percent lower all-cause ED visit rate and a numerically lower proportion of inpatient hospitalisations (11.1 percent vs. 14.8 percent). Estimated mean monthly direct healthcare costs were significantly lower for UZEDY (USD 4,688.10 vs. USD 5,724.80), delivering an adjusted mean monthly savings of USD 1,036.70 per patient.

Matched cohorts compared once-monthly UZEDY to risperidone microspheres every-2-weeks, aripiprazole once-monthly and haloperidol decanoate once-monthly. The greatest differences were observed against risperidone microspheres, where UZEDY patients achieved 3.6x higher odds of adherence (OR: 3.6), an 80 percent lower likelihood of discontinuation (OR: 0.2) and lower rates of ED visits and hospitalisations. UZEDY patients also had lower ED visit rates versus haloperidol decanoate once-monthly, while outcomes versus aripiprazole once-monthly were generally comparable.

John M Kane, MD, Professor of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, said, “As clinicians, it is frustrating to watch patients with schizophrenia struggle through cycles of relapse and end up back in the emergency room. We need to think differently about how we use Long-Acting Injectables. This observational data shows that patients receiving UZEDY had greater treatment continuity and fewer Emergency Department visits, reinforcing the potential of this approach to help patients stay stable while reducing pressure on an already strained healthcare system.”